Short-term effect of mirabegron on female sexual function in women with overactive bladder.

IF 0.8 Q4 UROLOGY & NEPHROLOGY
Nihat Karabacak, Murat Yavuz Koparal, Kadir Şerefhan Erten, Serhat Çetin, Metin Onaran, İlker Şen
{"title":"Short-term effect of mirabegron on female sexual function in women with overactive bladder.","authors":"Nihat Karabacak, Murat Yavuz Koparal, Kadir Şerefhan Erten, Serhat Çetin, Metin Onaran, İlker Şen","doi":"10.1177/03915603251316699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a common syndrome that can negatively affect patients' daily activities, sleep patterns, mental health, sexual function, and general health. In addition to reducing the frequency of attacks, treatment of OAB can be expected to improve the psychological and sexual health of patients.</p><p><strong>Aims: </strong>To evaluate the effects of mirabegron used in the treatment of overactive bladder (OAB) on female sexual function (FSF).</p><p><strong>Methods: </strong>This retrospective study includes 48 sexually active women who were diagnosed with overactive bladder and treated with a daily oral dose of 50 mg mirabegron between November 2021 and March 2022. The evaluation of FSF was conducted using female sexual function index (FSFI) along with urinary parameters before the start of the treatment and at the 6th week of the treatment.</p><p><strong>Results: </strong>In the study, out of 48 participants, 40 (83.3%) were identified with the dry type and 8 (16.7%) with the wet type OAB. The median age when diagnosed was 43.5 years. Although the decrease in the Overactive Bladder Questionnaire (OAB-V8) score did not reach statistical significance in the entire patient group after treatment (<i>p</i> = 0.058), a statistically significant decrease in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score was detected in the wet type OAB group (<i>p</i> < 0.001). During the assessment of sexual function, there was a statistically significant increase in the FSFI score, from 21.4 to 23.05, by the 6th week of treatment (<i>p</i> = 0.017). Specifically, the scores for desire, lubrication, and satisfaction showed a statistically significant post-treatment improvement (<i>p</i> < 0.001, <i>p</i> = 0.049, and <i>p</i> = 0.035, respectively).</p><p><strong>Conclusion: </strong>The study indicates that a 6-week regimen of a daily 50 mg mirabegron dose enhanced sexual function in women. This beneficial impact of mirabegron on sexual health should be taken into account when selecting a treatment for OAB.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251316699"},"PeriodicalIF":0.8000,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251316699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Overactive bladder (OAB) is a common syndrome that can negatively affect patients' daily activities, sleep patterns, mental health, sexual function, and general health. In addition to reducing the frequency of attacks, treatment of OAB can be expected to improve the psychological and sexual health of patients.

Aims: To evaluate the effects of mirabegron used in the treatment of overactive bladder (OAB) on female sexual function (FSF).

Methods: This retrospective study includes 48 sexually active women who were diagnosed with overactive bladder and treated with a daily oral dose of 50 mg mirabegron between November 2021 and March 2022. The evaluation of FSF was conducted using female sexual function index (FSFI) along with urinary parameters before the start of the treatment and at the 6th week of the treatment.

Results: In the study, out of 48 participants, 40 (83.3%) were identified with the dry type and 8 (16.7%) with the wet type OAB. The median age when diagnosed was 43.5 years. Although the decrease in the Overactive Bladder Questionnaire (OAB-V8) score did not reach statistical significance in the entire patient group after treatment (p = 0.058), a statistically significant decrease in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score was detected in the wet type OAB group (p < 0.001). During the assessment of sexual function, there was a statistically significant increase in the FSFI score, from 21.4 to 23.05, by the 6th week of treatment (p = 0.017). Specifically, the scores for desire, lubrication, and satisfaction showed a statistically significant post-treatment improvement (p < 0.001, p = 0.049, and p = 0.035, respectively).

Conclusion: The study indicates that a 6-week regimen of a daily 50 mg mirabegron dose enhanced sexual function in women. This beneficial impact of mirabegron on sexual health should be taken into account when selecting a treatment for OAB.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Urologia Journal
Urologia Journal UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
12.50%
发文量
66
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信